BENZODIAZEPINES AS SOLE TREATMENT vs placebo
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
1 finding from 1 review
- no estimate extracted4 studies · 161 participantsVery low
Findings
What do systematic reviews say?
2,087 questions · 2,360 findings · 390 reviews
No studies found 224 · 9.5%GRADE not reported 603 · 25.6%Very low 555 · 23.5%Low 548 · 23.2%Moderate 312 · 13.2%High 118 · 5%
Benzodiazepines vs antipsychotics
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
- RR 0.73 [0.45, 1.18]13 studies · 738 participantsVery low
Benzodiazepines vs antipsychotics
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to adverse effects (overall tolerability… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
- RR 13 [0.78, 216.39]5 studies · 444 participantsVery low
Technology‐mediated psychoeducation vs usual care
Leaving the study early · schizophrenia
It is very uncertain whether technology‐mediated psychoeducation changes compliance/satisfaction: leaving the study early ‐ any reason compared with standard care intervention (very low certainty).
1 finding from 1 review
- Information and communication technology in patient education and support for people with schizophrenia 2012 · Cochrane Headline outcomes onlyRR 1.24 [0.81, 1.88]2 studies · 116 participantsVery low
Intervention not reported
Early mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower early mortality Rates of patients (low certainty).
1 finding from 1 review
- Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in… 2012 · Cochrane Headline outcomes onlyRR 0.32 [0.13, 0.77]8 studies · 2143 participantsLow
Intervention not reported
Leaving the study early ‐ Adverse event: Short‐term · schizophrenia
The intervention showed no clear difference in leaving the study early ‐ Adverse event: Short‐term; GRADE not reported.
1 finding from 1 review
- RR 1.91 [0.8, 4.61]6 studies · 428 participantsGRADE not reported
Paliperidone palmitate vs placebo
Leaving the study early · patients with schizophrenia
Paliperidone palmitate leads to lower leaving the study early ‐ any reason Reported by trial author compared with placebo (high certainty).
1 finding from 1 review
- RR 0.76 [7, 84]5 studies · 2183 participantsHigh
Paliperidone palmitate vs risperidone long‐acting injection
Leaving the study early · patients with schizophrenia
Paliperidone palmitate showed no clear difference in leaving the study early ‐ any reason Reported by trial author compared with risperidone long‐acting injection (high certainty).
1 finding from 1 review
- RR 1.12 [1, 1.25]2 studies · 1969 participantsHigh
Paliperidone palmitate vs risperidone long‐acting injection
Leaving the study early ‐ lack of efficacy Reported by trial author · patients with schizophrenia
Paliperidone palmitate probably leads to higher leaving the study early ‐ lack of efficacy Reported by trial author compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
- RR 1.35 [1.06, 1.71]2 studies · 1969 participantsModerate
Intervention not reported
Yearly number of Philippine nurses migrating to the USA · Nurses in The Philippines
1 finding from 1 review
- Interventions to reduce emigration of health care professionals from low‐ and middle‐income countries 2011 · Cochrane Headline outcomes onlyno estimate extracted1 study · 1 participantsModerate
Intervention not reported
Non‐compliance leaving the study early (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted6 studies · 411 participantsModerate
CHLORPROMAZINE vs haloperidol
Leaving the study early · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes leaving the study early compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
- RR 2 [0.2, 19.78]1 study · 30 participantsVery low
Levomepromazine vs Typical antipsychotics
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
1 finding from 1 review
- RR 1.11 [0.45, 2.74]1 study · 41 participantsLow
Levomepromazine vs atypical antipsychotics
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).
1 finding from 1 review
- RR 0.83 [0.4, 1.74]2 studies · 106 participantsVery low
Levomepromazine vs atypical antipsychotics
Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).
1 finding from 1 review
- RR 5 [0.25, 98.27]1 study · 42 participantsModerate
Levomepromazine vs atypical antipsychotics
Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).
1 finding from 1 review
- RR 0.33 [0.01, 7.74]1 study · 42 participantsLow
Levomepromazine vs Typical antipsychotics
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).
1 finding from 1 review
- RR 0.95 [0.22, 4.18]1 study · 41 participantsLow
Levomepromazine vs Typical antipsychotics
Withdrawals due to adverse events · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).
1 finding from 1 review
- RR 4.77 [0.24, 93.67]1 study · 41 participantsLow
Levomepromazine vs Typical antipsychotics
Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia
It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).
1 finding from 1 review
- RR 2 [0.2, 19.62]1 study · 28 participantsVery low
Levomepromazine vs Typical antipsychotics
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
- RR 0.4 [0.09, 1.81]1 study · 38 participantsModerate